

In the Claims

Claims 1-48 (previously canceled)

49. (Currently amended) A method for treating a subject for ~~an allergic or hypersensitivity condition~~ Type I allergy comprising administering to the subject ~~an a therapeutically effective amount of an agent that is selected from the group consisting of Etx, Ctx, EtxB, and CtxB, antibodies, and derivatives of antibodies,~~ that bind to GM1.

Claims 50-52 (previously cancelled)

53. (Currently amended) A The method according to claim 49 wherein the agent is EtxB.

54. (Currently amended) A The method according to claim 66 which is a treatment for asthma.

55. (Currently amended) A The method according to claim 49 wherein the agent is CtxB.

56. (Currently amended) A method for treating a subject for ~~an allergic or hypersensitivity condition~~ Type I allergy comprising administering to the subject ~~an a therapeutically effective amount of an agent that is selected from the group consisting of Etx, Ctx, EtxB, and CtxB, antibodies, and derivatives of antibodies,~~ that bind to GM1, wherein the agent is administered with an antigen/allergen and is not coupled to an antigen.

Claims 57-58 (Previously cancelled)

59. (Currently amended) A The method according to claim 56 wherein the agent is EtxB.

60. (Currently amended) A The method according to claim 69 which is a treatment for asthma.

61. (Currently amended) A method for treating a subject for ~~an allergic or hypersensitivity condition~~ Type I allergy comprising administering to the subject an effective amount of an agent selected from the group consisting of CtxB, and EtxB, ~~antibodies, and derivatives of antibodies,~~ that modify a GM1- associated activity, and is not coupled to an antigen.

62. (Currently amended) A The method according to claim 61 wherein the agent is CtxB.

63. (Currently amended) A The method according to claim 61 wherein the agent is EtxB.

64. (Currently amended) A The method according to claim 61 which is a treatment for asthma.

Claim 65 (Previously cancelled)

66. (Currently amended) A The method according to claim 49 wherein the ~~allergic condition~~ Type I allergy is selected from the group consisting of asthma, allergic cough, allergic rhinitis, ~~and~~ conjunctivitis, atopic eczema, ~~and~~ dermatitis, urticaria, hives, insect bite allergy, dietary allergy, and drug allergies.

67. (Cancelled) A ~~method according to claim 49 wherein the hypersensitivity condition is contact sensitivity.~~

68. (Currently amended) A The method according to claim 66 which is a treatment for allergic rhinitis.

69. (Currently amended) A The method according to claim 56 wherein the allergic condition Type I allergy is selected from the group consisting of asthma, allergic cough, allergic rhinitis, and conjunctivitis, atopic eczema, and dermatitis, urticaria, hives, insect bite allergy, dietary allergy, and drug allergies.

70. (Cancelled) A ~~method according to claim 56 wherein the hypersensitivity condition is contact sensitivity induced by plant poisoning.~~

71. (Currently amended) A The method according to claim 56 wherein the agent is CtxB.

72. (Currently amended) A The method according to claim 69 which is a treatment for allergic rhinitis.

73. (Currently amended) A The method according to claim 61 wherein the allergic condition is selected from the group consisting of asthma, allergic cough, allergic rhinitis, and conjunctivitis, atopic eczema, and dermatitis, urticaria, hives, insect bite allergy, dietary allergy, and drug allergies.

74. (Cancelled) A ~~method according to claim 61 wherein the hypersensitivity condition is contact sensitivity.~~

75. (Currently amended) A The method according to claim 61 which is a treatment for allergic rhinitis.

76. (Currently amended) A method for treating a subject for ~~an allergic or hypersensitivity condition~~ Type I allergy comprising administering to the subject an effective amount of an agent that is selected from the group consisting of Etx, Ctx, EtxB, and CtxB, ~~antibodies, and derivatives of antibodies~~ that modifies a GM1- associated activity, wherein the agent is administered with an antigen/allergen.

77. (Currently amended) A The method according to claim 76 wherein the ~~allergic condition~~ Type I allergy is selected from the group consisting of asthma, allergic cough, allergic rhinitis and conjunctivitis, atopic eczema and dermatitis, urticaria, hives, insect bite allergy, dietary allergy and drug allergies.

78. (Cancelled) A ~~method according to claim 76 wherein the hypersensitivity condition is contact sensitivity.~~

79. (Currently amended) A The method according to claim 76 wherein the agent is EtxB.

80. (Currently amended) A The method according to claim 76 wherein the agent is CtxB.

81. (Currently amended) A The method according to claim 77 which is a treatment for asthma.

82. (Currently amended) A The method according to claim 77 which is a treatment for allergic rhinitis.

83. (New) A method for treating a subject for Type I allergies comprising coadministering to the subject a therapeutically effective amount of an agent selected from the group consisting of Etx, Ctx, EtxB, and CtxB; and an antigen/allergen; wherein said agent is not coupled to the antigen/allergen.